Clostridium difficile (C. difficile) is a major cause of hospital-acquired diarrhea, known as C. difficile-associated disease (CDAD), in the United States, with over 250,000 cases annually and healthcare costs exceeding $1 billion. The rise in CDAD cases is attributed to improved detection methods, increased antibiotic use, and hospital contamination with C. difficile spores. The two major toxins produced by C. difficile, TcdA and TcdB, are key virulence factors and primary diagnostic markers. These toxins are glucosyltransferases that inactivate small GTPases like Rho, Rac, and Cdc42, leading to cellular dysfunction and disease. TcdA and TcdB are among the largest bacterial toxins and are part of the large clostridial toxin family, which includes toxins from other clostridial species. TcdA and TcdB are encoded in a 19.6-kb pathogenicity locus and are regulated by environmental signals. They are involved in cell entry, receptor binding, and intracellular modification of targets. TcdA and TcdB are primarily responsible for the pathogenesis of C. difficile-associated disease, with TcdA playing a more direct role in disease development. TcdB, while less understood, can contribute to disease, especially in TcdA-negative strains. TcdA and TcdB are also important in cell biology research, serving as tools for studying cellular processes. The mechanisms of action of TcdA and TcdB involve receptor-mediated endocytosis, membrane translocation, and modification of intracellular targets. TcdA and TcdB target the actin cytoskeleton, leading to cell rounding, membrane blebbing, and apoptosis. They also affect GTPase signaling pathways, which regulate cell structure and function. TcdA and TcdB contribute to the pathogenesis of C. difficile by inducing inflammation, disrupting tight junctions, and causing epithelial cell death. These toxins are implicated in the development of pseudomembranous colitis, a severe form of CDAD. The role of TcdA and TcdB in disease is supported by various studies showing their involvement in cell death, inflammation, and tissue damage. TcdA and TcdB are also important in the diagnosis of C. difficile disease, as they are detected in the stools of patients through antibody-based and cytotoxicity assays. Recent studies have shown that TcdA and TcdB can be used to develop new diagnostic tools and therapies for C. difficile-associated disease. The understanding of TcdA and TcdB has advanced significantly in the past 15 years, providing insights into the molecular mechanisms of C. difficile pathogenesis.Clostridium difficile (C. difficile) is a major cause of hospital-acquired diarrhea, known as C. difficile-associated disease (CDAD), in the United States, with over 250,000 cases annually and healthcare costs exceeding $1 billion. The rise in CDAD cases is attributed to improved detection methods, increased antibiotic use, and hospital contamination with C. difficile spores. The two major toxins produced by C. difficile, TcdA and TcdB, are key virulence factors and primary diagnostic markers. These toxins are glucosyltransferases that inactivate small GTPases like Rho, Rac, and Cdc42, leading to cellular dysfunction and disease. TcdA and TcdB are among the largest bacterial toxins and are part of the large clostridial toxin family, which includes toxins from other clostridial species. TcdA and TcdB are encoded in a 19.6-kb pathogenicity locus and are regulated by environmental signals. They are involved in cell entry, receptor binding, and intracellular modification of targets. TcdA and TcdB are primarily responsible for the pathogenesis of C. difficile-associated disease, with TcdA playing a more direct role in disease development. TcdB, while less understood, can contribute to disease, especially in TcdA-negative strains. TcdA and TcdB are also important in cell biology research, serving as tools for studying cellular processes. The mechanisms of action of TcdA and TcdB involve receptor-mediated endocytosis, membrane translocation, and modification of intracellular targets. TcdA and TcdB target the actin cytoskeleton, leading to cell rounding, membrane blebbing, and apoptosis. They also affect GTPase signaling pathways, which regulate cell structure and function. TcdA and TcdB contribute to the pathogenesis of C. difficile by inducing inflammation, disrupting tight junctions, and causing epithelial cell death. These toxins are implicated in the development of pseudomembranous colitis, a severe form of CDAD. The role of TcdA and TcdB in disease is supported by various studies showing their involvement in cell death, inflammation, and tissue damage. TcdA and TcdB are also important in the diagnosis of C. difficile disease, as they are detected in the stools of patients through antibody-based and cytotoxicity assays. Recent studies have shown that TcdA and TcdB can be used to develop new diagnostic tools and therapies for C. difficile-associated disease. The understanding of TcdA and TcdB has advanced significantly in the past 15 years, providing insights into the molecular mechanisms of C. difficile pathogenesis.